Lexicon Gains After FDA Approves Inpefa for Heart Failure (1)

(Updates with share move starting in headline; adds last two bullets)

Lexicon Pharmaceuticals is up 6.0% in extended trading Friday after saying the FDA granted approval to its Inpefa (sotagliflozin) tablets for the treatment of heart failure.

• The approval covers adults with heart failure, or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors
  • Encompasses heart failure patients across the full range of left ventricular ejection fraction, including preserved ejection fraction and reduced ejection fraction, and for patients with or without diabetes
  • Expects Inpefa be available by the end of June
• Conference call set for Tuesday at 8am New ...